Molecule to Market takes you inside the contract outsourcing space with industry insights and thoughts direct from the brains of the people that make the headlines (just think of your favourite podcast and that’s what we’re doing, but with drug supply chain shortages instead of unsolved crimes and life science leaders instead of sports stars). Talking everything from pharmaceutical contract research, development and manufacturing to clinical trial packaging, logistics and technology – Molecule to Market is a vital shot of infotainment for anyone who wants in on outsourcing.
All content for Molecule to Market: Inside the outsourcing space is the property of Raman Sehgal and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Molecule to Market takes you inside the contract outsourcing space with industry insights and thoughts direct from the brains of the people that make the headlines (just think of your favourite podcast and that’s what we’re doing, but with drug supply chain shortages instead of unsolved crimes and life science leaders instead of sports stars). Talking everything from pharmaceutical contract research, development and manufacturing to clinical trial packaging, logistics and technology – Molecule to Market is a vital shot of infotainment for anyone who wants in on outsourcing.
In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Stephen Dilly, Chairman, President and Chief Executive Officer at Codexis.
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Stephen, covering:
His journey of almost 40 years in the industry, including 20 years as a CEO.
Leading two therapeutic companies to two, successful, $billion+ exits...
Not making snap judgements and instant opinions early on in your role as a senior leader.
Why he took on the challenge of leading Codexis at this phase of his career.
The importance of values as guiding principles, and spending in-person time with your team.
As President & CEO of Codexis since August 2022, Stephen brings more than three decades of executive management experience in the biopharmaceutical industry. Most recently, he served as President and CEO of Sierra Oncology (NASDAQ: SRRA) through its recent sale to GlaxoSmithKline for $1.9 billion.
Previously, Dr. Dilly served as CEO of Aimmune Therapeutics, acquired by Nestle Health Science for $2.6 billion. Dr. Dilly has served in executive roles at Genentech, Chiron and SmithKline Beecham and has been associated with the development, approval and launch of more than twenty marketed drugs across multiple therapeutic areas. He holds both an MBBS and a PhD in Cardiac Physiology from the University of London.
Molecule to Market is also sponsored by Bora Pharma (boracdmo.com) and Charles River (www.criver.com), and supported by ramarketing.
Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
Molecule to Market: Inside the outsourcing space
Molecule to Market takes you inside the contract outsourcing space with industry insights and thoughts direct from the brains of the people that make the headlines (just think of your favourite podcast and that’s what we’re doing, but with drug supply chain shortages instead of unsolved crimes and life science leaders instead of sports stars). Talking everything from pharmaceutical contract research, development and manufacturing to clinical trial packaging, logistics and technology – Molecule to Market is a vital shot of infotainment for anyone who wants in on outsourcing.
